Clinical Trial Update: Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing fixed-duration versus continuous anti-CD38 monoclonal antibody therapy in transplant-ineligible older adults with newly diagnosed multip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anti-CD38 monoclonal antibody therapy

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Multiple Myeloma | Phase 3 | Status: RECRUITING